- Home
- CNMD vs CNTA Comparison
CNMD vs CNTA Comparison
Compare CNMD & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNMD | CNTA |
|---|---|---|
| Founded | 1970 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 2.3B |
| IPO Year | 1987 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNMD | CNTA |
|---|---|---|
| Price | $40.07 | $24.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $53.67 | $37.70 |
| AVG Volume (30 Days) | 669.5K | ★ 1.5M |
| Earning Date | 02-04-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $1,347,470,000.00 | $15,000,000.00 |
| Revenue This Year | $6.81 | N/A |
| Revenue Next Year | $5.23 | N/A |
| P/E Ratio | $19.49 | ★ N/A |
| Revenue Growth | 4.61 | ★ 118.88 |
| 52 Week Low | $38.32 | $9.60 |
| 52 Week High | $74.70 | $30.58 |
Technical Indicators
Market Signals| Indicator | CNMD | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 41.72 | 38.02 |
| Support Level | $38.65 | $25.59 |
| Resistance Level | $40.81 | $30.02 |
| Average True Range (ATR) | 1.64 | 1.29 |
| MACD | -0.01 | -0.67 |
| Stochastic Oscillator | 26.30 | 10.14 |
Price Performance
Historical ComparisonAbout CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.